GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
LONDON, July 21, 2010 /PRNewswire-FirstCall/ -- In an interview with financial broadcaster http://www.cantos.com, GlaxoSmithKline CEO Andrew Witty says one-offs held back sales growth in Q2 but highlights the strong underlying performance of Emerging Markets, Consumer and Vaccines.
The Pharma boss also points to "an unprecedented" five new drugs in late stage trials as a sign of the successful restructuring of the group.
Mr Witty tackles the ongoing Avandia controversy and the recent GBP1.6bn payout, saying "it was actually in the best interest of the company's shareholders."
The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline.
Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.
SOURCE GlaxoSmithKline
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article